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ABSTRACT: By screening an epigenetic compound library, we identified that UNC0638,
a highly potent inhibitor of the histone methyltransferases G9a and GLP, was a weak
inhibitor of SPIN1 (spindlin 1), a methyllysine reader protein. Our optimization of this
weak hit resulted in the discovery of a potent, selective, and cell-active SPIN1 inhibitor,
compound 3 (MS31). Compound 3 potently inhibited binding of trimethyllysine-
containing peptides to SPIN1, displayed high binding affinity, was highly selective for
SPIN1 over other epigenetic readers and writers, directly engaged SPIN1 in cells, and was
not toxic to nontumorigenic cells. The crystal structure of the SPIN1−compound 3
complex indicated that it selectively binds tudor domain II of SPIN1. We also designed a
structurally similar but inactive compound 4 (MS31N) as a negative control. Our results
have demonstrated for the first time that potent, selective, and cell-active fragment-like
inhibitors can be generated by targeting a single tudor domain.
■ INTRODUCTION
Epigenetic regulation plays an important role in gene
expression and transcription, which are critical for a variety
of cellular processes. Epigenetic modifications can be divided
into two main categories: DNA methylation and histone
modifications.1 Histone post-translational modifications
(PTMs)2 require three types of proteins: the enzymes that
create the modifications (the “writers”),3−7 the enzymes that
remove the modifications (the “erasers”),7,8 and the proteins
that recognize the modifications (the “readers”).9,10 Growing
evidence suggests that reader proteins are implicated in a
number of human diseases including cancer.11 Therefore,
reader proteins are increasingly being pursued as potential
therapeutic targets.12,13 However, unlike the significant
progress made in the discovery of small-molecule inhibitors
of histone methyltransferases (MTs), bromodomain-contain-
ing proteins (which recognize acetylated lysine residues), and
histone demethylases,5−7,14−16 only a very limited number of
small-molecule inhibitors targeting methyllysine reader pro-
teins have been reported, including UNC1215 (a potent and
selective L3MBTL3 inhibitor), UNC3866 (a potent and
selective peptide-based CBX7/4 inhibitor), EML631 (a
selective and cell-active SPIN1 inhibitor with 685 Da molecule
Received: March 25, 2019
Published: July 1, 2019
Article
pubs.acs.org/jmcCite This: J. Med. Chem. 2019, 62, 8996−9007
© 2019 American Chemical Society 8996 DOI: 10.1021/acs.jmedchem.9b00522


























































































weight), and A366 (a nonselective SPIN1 inhibitor) (Figure
1).17−24 Furthermore, it is quite challenging to achieve
sufficient potency and selectivity by targeting a single
methyllysine reader domain such as a tudor domain or
malignant brain tumor (MBT) domain as several reported
potents, and selective inhibitors of methyllysine reader proteins
such as UNC1215 and EML631 achieved their potency and
selectivity by simultaneously targeting two methyllysine reader
domains.21,24
SPIN1 (spindlin 1) is a chromatin reader protein, which
recognizes trimethylated histone H3 lysine 4 (H3K4me3)
through the protein−protein interaction at the defined
“aromatic cage” in tudor domain II, and the interaction
between asymmetrically dimethylated histone H3 arginine 8
(H3R8me2a) and tudor domain I further increases the
affinity.25−27 SPIN1 was found to be overexpressed in several
types of malignant tumors, including ovarian cancer, certain
types of liver carcinomas, nonsmall-cell lung cancers, and
liposarcoma.28−33 Upregulation of SPIN1 has been shown to
increase cellular proliferation, abnormal mitosis, and chromo-
somal instability.34 In addition, SPIN1 is involved in several
signaling pathways, such as Wnt/TCF-4 and RET signaling
pathways.29,35 Therefore, small molecules that selectively
disrupt the protein−protein interactions between SPIN1 and
its respective binding partners (such as H3K4me3) are
valuable chemical tools for investigating biological functions
of SPIN1 and assessing the potential of SPIN1 as a therapeutic
target. Two small-molecule inhibitors of SPIN1 have been
reported to date. We previously reported that A366 (Figure 1)
was a potent but not a selective inhibitor of SPIN1 (Figure
S1).23 A class of bivalent compounds represented by EML631
(Figure 1) that occupy tudor domains I and II of SPIN1 were
shown to be selective and cell-active inhibitors of SPIN1 with a
relatively weak binding affinity.24 The relatively high molecule
weight of EML631 (685 Da) may also render difficulties for
further optimization.
Fragment-like inhibitors may possess high intrinsic binding
energy and often exhibit high ligand efficiency (LE).36,37 Their
low molecular weights leave large room for installing additional
functional groups in lead optimization, which could result in
Figure 1. Representative inhibitors of methyllysine reader proteins.
Figure 2. Discovery of compound 3 and its inactive control compound 4.
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drug candidates with higher potency and improved phys-
icochemical properties, such as aqueous solubility, membrane
permeability, and oral bioavailability. Therefore, fragment-like
inhibitors are valuable starting points for drug development
efforts, in addition to being useful tools for chemical biology
studies.38 Here, we report our discovery of a fragment-like
inhibitor, compound 3 (MS31) with a molecular weight less
than 350, which potently and selectively disrupted the
protein−protein interactions between SPIN1 and H3K4me3.
■ RESULTS AND DISCUSSION
Discovery of a Fragment-like Hit (Compound 2).
Using AlphaLISA and fluorescence polarization (FP)-based
biochemical assays, we screened the epigenetic compound
library generated by our lab, which includes hundreds of small-
molecule modulators of epigenetic writers, readers, and erasers,
and identified UNC0638 (compound 1, Figure 2), a highly
potent inhibitor of the histone MTs G9a and GLP,39,40 as a
weak SPIN1 inhibitor (IC50 = 3.2 ± 0.3 μM (AlphaLISA) and
7.4 ± 0.4 μM (FP)) (Figure S1). To improve potency and
selectivity of UNC0638 for SPIN1 over G9a and GLP, we
analyzed the cocrystal structure of compound 1 in the complex
with G9a (PDB: 3RJW)41 and the cocrystal structure of SPIN1
in the complex with a H3 peptide (PDB: 4H75)26 and
generated a docking model of compound 1 in the complex
with SPIN1 (Figure S2). The docking model suggests that the
3-(pyrrolidin-1-yl)propoxyl group of compound 1 likely
mimics H3K4me3, interacting with the aromatic cage of the
SPIN1 tudor domain II, while the 4-amino piperidine group on
the quinazoline ring extends out of the SPIN1 tudor domain II
and the 2-cyclohexyl group on the quinazoline ring does not
appear to make any interactions. Based on these observations,
we simplified the structure of compound 1 by replacing the
2,4-disubstituted quinazoline with a disubstituted phenyl ring
while keeping the 3-(pyrrolidin-1-yl)propoxyl and methoxy
groups. As a result, we discovered a much simpler compound
with a molecular weight less than 300, 2 (Figure 2), as a SPIN1
inhibitor. Importantly, compared with compound 1, com-
pound 2 showed approximately 10-fold improvement in
potency for SPIN1 (IC50 = 338 ± 30 nM (AlphaLISA) and
741 ± 46 nM (FP)) (Figure 3A,B). We determined that
compound 2 bound SPIN1 with a KD value of 390 ± 54 nM
using isothermal titration calorimetry (ITC) (Figure 3C). To
our delight, 2 did not bind either G9a or GLP using the same
ITC experiments (Figures 3D and S3).
Discovery of Compound 3. To improve potency of
compound 2, we replaced the pyrrolidinyl group with an
isoindolinyl group, trying to achieve some π−π stacking
interactions in the aromatic cage of the SPIN1 tudor domain
II. As what we expected, compared with 2, the resulting
compound 3 (Figure 2) showed >4-fold higher potency for
SPIN1 (IC50 = 77 ± 3 nM (AlphaLISA) and 243 ± 10 nM
(FP)) (Figure 4A), while maintaining a low molecular weight
of 341. The potency of compound 3 is comparable to that of
A366 (IC50 = 72 ± 2 nM (AlphaLISA) and 207 ± 10 nM
(FP)) (Figure S1), a G9a/GLP inhibitor42 whose SPIN1
activity was previously reported by us.23 We next assessed the
binding affinity of compound 3 to SPIN1 using ITC and found
that it bound SPIN1 with a KD value of 91 ± 4 nM (Figure 4B
left panel), which is consistent with its potency in biochemical
assays. The molar ratio of 1 was observed, suggesting that
compound 3 likely bound only one out of three tudor domains
of SPIN1. Importantly, similar to compound 2, compound 3
did not bind either G9a or GLP in ITC experiments (Figure
Figure 3. Compound 2 is a selective SPIN 1 inhibitor. Compound 2 inhibited the interactions between SPIN1 and H3K4me3 in a concentration
dependent manner with IC50 values of (A) 338 ± 30 nM in AlphaLISA assay (n = 3) and (B) 741 ± 46 nM in FP assay (n = 3). (C) Compound 2
bound SPIN1 with a KD value of 390 ± 54 nM in ITC assay (n = 3). (D) Compound 2 did not bind G9a.
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4C). In addition, compound 3 showed moderate binding
affinities (ranging from 170 nM to 1.7 μM) to other closely
related SPIN subfamily members (SPIN2B, SPIN3, and
SPIN4) in ITC experiments (Figure S4), suggesting similar
domain architectures and binding modes amongst the SPIN
subfamily members.43−45 To further assess its selectivity, we
tested compound 3 against 33 MTs (including G9a and GLP)
and 5 acetyltransferases and found that it did not significantly
inhibit these MTs and acetyltransferases at up to 50 μM
(Figure 5A and Table S1). In addition, we assessed selectivity
of compound 3 against 20 methyllysine, methylarginine, and
acetyllysine reader proteins using a thermal shift assay and
found that compound 3 did not induce a significant thermal
shift for any of the 20 reader proteins at 20 or 200 μM (Figure
5B and Table S2). Thus, compound 3 is selective over a broad
range of epigenetic proteins.
Determination of the Cocrystal Structure of Com-
pound 3 in the Complex with SPIN1. We next solved the
X-ray crystal structure of SPIN1 in the complex with
compound 3 at 1.6 Å resolution (PDB code: 6QPL, Figure
6, and Table S3). As illustrated in Figure 6A, compound 3 only
occupied the SPIN1 tudor domain II, which recognizes
H3K4me3. As expected, the isoindolinyl group occupied the
aromatic cage (Figure 6B,C). The protonated amino group in
the isoindolinyl group not only formed a hydrogen bond (H-
bond) with Y179 but also interacted with Y170, W151, and
F141 in the aromatic cage through cation−π interactions
(Figure 6C). The phenyl ring of the isoindoline group
interacted with W151 through π−π stacking, which may
explain the increased potency of compound 3 over compound
2 (Figure 6C). Besides these important interactions formed by
the isoindolinyl group, two aminomethylene side chains
formed a few critical H-bonds. The amino group of the 3-
aminomethylene side chain formed a H-bond with D95 on the
loop of the tudor domain I of SPIN1 (Figure 6C). The amino
group of the 5-aminomethylene side chain formed a direct H-
bond with D184 on the α-helix of tudor domain II and two
water-mediated H-bonds with M140 and D189. Disrupting
these H-bond interactions by switching the 5-aminomethylene
group of compound 3 to an amido group resulted in a
structurally similar but inactive compound, 4 (Figure 2), which
was completely inactive in the SPIN1 AlphaLISA and FP
assays (Figure 4A). In addition, compound 4 did not show
detectable binding affinity to SPIN1 in ITC experiments
(Figure 4B right panel). Thus, compound 4 could be used as a
negative control in chemical biology studies.
Evaluation of Compound 3 in Cellular Assays. Using a
NanoBRET target engagement assay,46 we next demonstrated
that compound 3 can engage SPIN1 in cells. As illustrated in
Figure 7A,B, compound 3, but not compound 4, reduced the
interaction between SPIN1 and histone H3 in U2OS cells in a
concentration-dependent manner with an IC50 value of 3.2 ±
0.7 μM. Thus, compound 3 is cell permeable and can
effectively engage SPIN1 in cells. Finally, we assessed off-target
toxicity of compound 3 in two transformed cell lines, C2C12
and 293T, and one normal human primary fibroblasts cell line,
HFF-1. We found that compound 3 was not toxic to these cells
at up to 30 μM (Figure 7C). Thus, compound 3 is a useful tool
compound for cellular studies.
Chemical Synthesis. Compounds 2, 3, and 4 were
synthesized using the synthetic routes shown in Schemes 1−3.
The preparation of compound 2 was started from 3,5-
dibromo-2-methoxyphenol (5).47 Protection of the phenol
group using benzyl bromide under basic conditions provided
benzyl ether intermediate 6. Next, the dibromo groups on the
phenyl ring were converted to dicyano groups under
Rosenmund−von Braun reaction conditions, resulting in
intermediate 7. Benzyl ether deprotection under palladium-
catalyzed hydrogenation conditions provided phenol 8, which
was subsequently converted to 3-chloropropyl ether 9.
Substitution of the chloro group with pyrrolidine in the
presence of potassium iodide yielded intermediate 10. Lastly,
reduction of the dicyano groups under Raney nickel-mediated
hydrogenation provided compound 2 (Scheme 1).
Compound 3 was synthesized following similar procedures
for preparation of compound 2. Briefly, isoindoline sub-
stitution of the chloro group of intermediate 9 yielded
Figure 4. Compound 3 is a potent SPIN1 inhibitor. (A) Compound
3, but not compound 4, potently inhibited the interactions between
SPIN1 and H3K4me3 with IC50 values of 77 ± 3 nM in AlphaLISA
assay (n = 3) and 243 ± 10 nM in FP assay (n = 3). (B) Compound 3
bound SPIN1 with a KD value of 91 ± 4 nM (n = 3) while compound
4 did not bind SPIN1 in ITC experiments. (C) Compound 3 did not
bind either G9a or GLP in ITC experiments.
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compound 11. The dicyano groups were subsequently reduced
to diaminomethylene groups to afford compound 3 (Scheme
2).
Compound 4 was prepared from commercially available
compound 12. The carboxylic acid and phenolic hydroxyl
groups of 12 were simultaneously protected as benzyl ester and
benzyl ether groups, respectively, to provide intermediate 13.
The bromo group of 13 was substituted with the cyano group
using the Rosenmund−von Braun reaction to yield inter-
mediate 14. After the hydrolysis of the benzyl ester under basic
conditions, the resulting carboxylic acid was activated as acid
chloride, which was subsequently converted to amide 16 in the
presence of ammonium hydroxide aqueous solution. The
benzyl ether was deprotected to provide intermediate 17 with a
free phenol group, which was converted to the 3-
isoindolinylpropyl ether product 4 in three steps (Scheme
3), using the similar reaction sequences for the preparation of
compounds 2 and 3.
■ CONCLUSIONS
In summary, we optimized compound 1, a weak SPIN1 but
highly potent G9a/GLP inhibitor, into compound 3, a potent
Figure 5. Compound 3 is a selective SPIN1 inhibitor. (A) Compound 3 did not significantly inhibit the enzymatic activity of 33 MTs and 5
acetyltransferases at 10 μM (blue) and 50 μM (red). (B) Compound 3 did not induce significant thermal shifts for 20 methyllysine, methylarginine
and acetyllysine reader proteins at 20 μM or 200 μM in thermal shift assays (n = 2).
Figure 6. Crystal structure of the SPIN1−compound 3 complex. (A) Compound 3 (green) occupies the tudor domain II (pink) of SPIN1. (B)
Electrostatic potential surface view of the structure, ranging from −6 kT/e (red) to +6 kT/e (blue). (C) Close-up view of the SPIN1−compound 3
complex structure with key ligand−protein interactions. Yellow dashes, hydrogen bonds. Red balls, water molecules.
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and selective fragment-like inhibitor of SPIN1. Compound 3
displayed high potency in SPIN1 biochemical assays (IC50 =
77 nM (AlphaLISA) and 243 nM (FP)) and high binding
affinity to SPIN1 (KD = 91 nM) by ITC. Compound 3 was
completely inactive against G9a and GLP and selective for
SPIN1 over a broad range of epigenetic proteins. We also
obtained an X-ray crystal structure of SPIN1 in the complex
with compound 3, which confirmed that compound 3
occupied tudor domain II of SPIN1. Based on the cocrystal
structure, we designed compound 4, a close analogue of
compound 3 as a negative control, which was indeed inactive
in SPIN1 biochemical and biophysical assays. We demon-
strated that compound 3, but not the negative control
compound 4, engaged SPIN1 in cells using a NanoBRET
assay, and compound 3 was not toxic in the nontumorigenic
cells evaluated. Thus, compound 3 and compound 4 are a pair
of useful tool compounds for investigating biological functions
and disease associations of SPIN1. Remarkably, compound 3
achieved high potency and selectivity for SPIN1 by targeting a
single methyllysine reader domain. These results have
demonstrated that it is feasible to generate potent, selective,
and cell-active inhibitors by targeting a single tudor domain
and paved the way for discovering improved inhibitors of
methyllysine reader proteins.
■ EXPERIMENTAL SECTION
Chemistry General Procedures. High-performance liquid
chromatography (HPLC) spectra for compounds were acquired
using an Agilent 1200 Series system with a DAD detector.
Chromatography was performed on a 2.1 × 150 mm Zorbax
300SB-C18 5 μm column with water containing 0.1% formic acid as
solvent A and acetonitrile containing 0.1% formic acid as solvent B at
a flow rate of 0.4 mL/min. The gradient program was as follows: 1% B
(0−1 min), 1−99% B (1−4 min), and 99% B (4−8 min). Ultra-
performance liquid chromatography (UPLC) spectra for compounds
were acquired using a Waters Acquity I-Class UPLC system with a
PDA detector. Chromatography was performed on a 2.1 × 30 mm
ACQUITY UPLC BEH C18 1.7 μm column with water containing 3%
acetonitrile, 0.1% formic acid as solvent A and acetonitrile containing
0.1% formic acid as solvent B at a flow rate of 0.8 mL/min. The
gradient program was as follows: 1−99% B (1−1.5 min), and 99−1%
B (1.5−2.5 min). High-resolution mass spectra (HRMS) data were
acquired in the positive ion mode using Agilent G1969A API-TOF
with an electrospray ionization (ESI) source. Nuclear magnetic
resonance (NMR) spectra were acquired on either a Bruker DRX-600
spectrometer (600 MHz 1H) or a Bruker DXI 800 MHz spectrometer
(800 MHz 1H, 200 MHz 13C). Chemical shifts are reported in ppm
(δ). Preparative HPLC was performed on Agilent Prep 1200 series
with an UV detector set to 254 nm. Samples were injected into a
Phenomenex Luna 75 × 30 mm, 5 μm, C18 column at room
temperature. The flow rate was 40 mL/min. A linear gradient was
used with 10% (or 50%) of MeOH (A) in H2O [with 0.1%
trifluoroacetic acid (TFA)] (B) to 100% of MeOH (A). HPLC and
UPLC were used to establish the purity of target compounds. All final
compounds had >95% purity using the HPLC and UPLC methods
described above. Compounds 2 and 3 were tested in biological assays
in their HCl salt forms and compound 4 in its CF3CO2H salt form.
(4-Methoxy-5-(3-(pyrrolidin-1-yl)propoxy)-1,3-phenylene)-
dimethanamine (2). Compound 2 was synthesized from the
intermediate 6 following the procedures described below. To a
solution of 10 (127 mg, 0.32 mmol) in MeOH (2 mL) was added
Raney Ni (50 mg), followed by aqueous ammonia solution (0.1 mL).
The mixture was stirred under a hydrogen atmosphere (1 atm) for 12
h, before the insoluble solid was filtered. The filtrate was collected and
concentrated. The resulting residue was purified by prep-HPLC to
Figure 7. Compound 3 binds SPIN1 in cells and shows no
cytotoxicity. (A) Compound 3 disrupted the interaction between
SPIN1 and histone H3 (IC50 = 3.2 ± 0.7 μM (n = 4)) in U2OS cells
in a NanoBRET assay. (B) Compound 4 was inactive in the
NanoBRET assay (n = 3). (C) Compound 3 was not toxic to C2C12
and 293T cell lines or primary fibroblasts HFF1, at up to 30 μM (n =
3). Indicated cell lines were cultured in the presence of indicated
concentrations of compound 3 for 6 days. Cell viability was measured
using Alamar blue.
Scheme 1. Synthesis of Compound 2a
aReagent and conditions: (a) BnBr, K2CO3, DMF, rt, 12 h, 90%; (b) CuCN, NMP, 170 °C, 18 h, 40%; (c) H2 (1 atm), 10% Pd/C, EtOAc, rt, 5 h;
(d) 1-bromo-3-chloropropane, DMF, rt, 12 h, 60% in 2 steps; (e) pyrrolidine, K2CO3, KI, DMF, 60 °C, 12 h, 80%; (f) H2 (1 atm), Raney Ni,
NH4OH, MeOH, rt, 12 h, 70%.
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yield the title compound as brown oil (90 mg, 70% yield). 1H NMR
(600 MHz, CD3OD): δ 7.38 (s, 1H), 7.16 (s, 1H), 4.28 (t, J = 5.5 Hz,
2H), 4.16 (s, 2H), 4.14 (s, 2H), 4.01 (s, 3H), 3.82−3.69 (m, 2H),
3.52−3.44 (m, 2H), 3.23−3.13 (m, 2H), 2.41−2.32 (m, 2H), 2.26−
2.16 (m, 2H), 2.14−2.04 (m, 2H). HPLC >95%, tR = 1.24 min.
HRMS (ESI-TOF) m/z: [M + H]+ calcd for C16H28N3O2, 294.2176;
found, 294.2150.
(5-(3-(Isoindolin-2-yl)propoxy)-4-methoxy-1,3-phenylene)-
dimethanamine (3). Compound 3 was synthesized from the
intermediate of 11 according to the procedures for the preparation
of 2 as brown oil (65% yield). 1H NMR (600 MHz, CD3OD): δ
7.49−7.42 (m, 4H), 7.40 (s, 1H), 7.15 (s, 1H), 5.02 (d, J = 13.8 Hz,
2H), 4.68 (d, J = 13.9 Hz, 2H), 4.33 (t, J = 5.8 Hz, 2H), 4.16 (s, 2H),
4.14 (s, 2H), 4.01 (s, 3H), 3.74 (t, J = 7.8 Hz, 2H), 2.50−2.38 (m,
2H). 13C NMR (200 MHz, MeOD): δ 151.60, 148.24, 133.57,
129.30, 128.79, 126.98, 122.93, 122.60, 115.77, 65.82, 60.35, 58.51,
52.32, 42.47, 38.30, 25.46. HPLC >95%, tR = 1.31 min. HRMS (ESI-
TOF) m/z: [M + H]+ calcd for C20H28N3O2, 342.2176; found,
342.2145.
3-(Aminomethyl)-5-(3-(isoindolin-2-yl)propoxy)-4-methox-
ybenzamide (4). Compound 4 was synthesized from intermediate
19 according to the procedures for the preparation of compound 2 as
brown oil (72% yield). 1H NMR (600 MHz, CD3OD): δ 7.67 (s,
1H), 7.59 (s, 1H), 7.48−7.44 (m, 4H), 5.08−4.94 (m, 2H), 4.77−
4.58 (m, 2H), 4.32 (t, J = 5.7 Hz, 2H), 4.22 (s, 2H), 3.99 (s, 3H),
3.78 (d, J = 7.8 Hz, 2H), 2.42−2.32 (m, 2H). 13C NMR (200 MHz,
MeOD): δ 169.50, 152.05, 148.83, 133.55, 129.93, 128.83, 126.40,
122.60, 121.41, 112.85, 70.05, 58.60, 55.26, 52.59, 38.20, 26.39.
UPLC >95%, tR = 0.66 min. HRMS (ESI-TOF) m/z: [M + H]
+ calcd
for C20H26N3O3, 356.1969; found, 356.1994.
1-(Benzyloxy)-3,5-dibromo-2-methoxybenzene (6). To a
solution of 547 (1.71 g, 6.1 mmol) in dimethylformamide (DMF)
(10 mL) was added K2CO3 (1.60 g, 11.6 mmol), followed by benzyl
bromide (0.89 mL, 7.5 mmol). The resulting suspension was stirred at
rt for 12 h, before water (10 mL) was added to quench the reaction.
The mixture was extracted with ether (3 × 20 mL). The combined
organic phase was dried with anhydrous Na2SO4, filtered, and
concentrated under reduced pressure. The resulting residue was
purified by flash chromatography to yield the title compound as the
white solid (2.05 g, 90% yield). 1H NMR (600 MHz, CDCl3): δ
7.49−7.36 (m, 5H), 7.33 (s, 1H), 7.08 (s, 1H), 5.12 (s, 2H), 3.89 (s,
3H).
5-(Benzyloxy)-4-methoxyisophthalonitrile (7). To a solution
of 6 (2.05 g, 5.5 mmol) in N-Methyl-2-pyrrolidone (NMP) (10 mL)
was added CuCN (1.08 g, 12.1 mmol). The mixture was heated in a
sealed tube for 18 h. After cooling to room temperature, aqueous
ammonia solution (2 mL) was added. The reaction was extracted with
ether (3 × 20 mL). The combined organic phase was dried with
anhydrous Na2SO4, filtered, and concentrated. The residue was
purified by flash chromatography to yield the title compound as
colorless oil (580 mg, 40% yield). 1H NMR (600 MHz, CDCl3): δ
7.49 (s, 1H), 7.48−7.40 (m, 5H), 7.37 (s, 1H), 5.18 (s, 2H), 4.18 (s,
3H). UPLC >95%, tR = 1.62 min.
5-(3-Chloropropoxy)-4-methoxyisophthalonitrile (9). To a
solution of 7 (580 mg, 2.2 mmol) in ethyl acetate (10 mL) was added
10% palladium on carbon (50 mg). The mixture was stirred in a
hydrogen atmosphere (1 atm) for 5 h, before being filtered. The
filtrate was concentrated. The resulting residue was dissolved in DMF
(5 mL). To the resulting solution was added K2CO3 (455 mg, 3.3
mmol), followed by 1-bromo-3-chloropropane (0.43 mL, 4.4 mmol).
The mixture was stirred at room temperature for 12 h, before water
was added to quench the reaction. The mixture was extracted with
ether (3 × 20 mL). The combined organic phase was combined, dried
over anhydrous Na2SO4, and concentrated. The resulting residue was
purified by flash chromatography to yield the title compound as
colorless oil (335 mg, 60% yield). 1H NMR (600 MHz, CDCl3): δ
7.50 (s, 1H), 7.37 (s, 1H), 4.24 (t, J = 5.8 Hz, 2H), 4.16 (s, 3H), 3.78
(t, J = 6.1 Hz, 2H), 2.39−2.32 (m, 2H). UPLC >95%, tR = 1.47 min.
4-Methoxy-5-(3-(pyrrolidin-1-yl)propoxy)isophthalonitrile
(10). To a solution of 9 (100 mg, 0.4 mmol) in DMF (2 mL) was
added pyrrolidine (84 μL, 1 mmol), K2CO3 (140 mg, 1 mmol), and
KI (15 mg, 0.1 mmol). The resulting suspension was heated at 60 °C
Scheme 2. Synthesis of Compound 3a
aReagent and conditions: (a) isoindoline, K2CO3, KI, DMF, 60 °C, 12 h, 60%; (b) H2 (1 atm), Raney Ni, NH4OH, MeOH, rt, 12 h, 65%.
Scheme 3. Synthesis of Compound 4a
aReagent and conditions: (a) BnBr, K2CO3, DMF, rt, 12 h, 91%; (b) CuCN, NMP, 170 °C, 18 h, 54%; (c) NaOH, MeOH, H2O, rt, 2 h. (d)
(COCl)2, DMF, CH2Cl2, rt, 1 h; NH4OH, 0 °C, 1 h, 41% in 3 steps; (e) H2 (1 atm), 10% Pd/C, EtOAc, rt, 5 h; (f) 1-bromo-3-chloropropane,
DMF, rt, 12 h, 55% in 2 steps; (g) isoindoline, K2CO3, KI, DMF, 60 °C, 12 h, 61%; (h) H2 (1 atm), Raney Ni, NH4OH, MeOH, rt, 12 h, 72%.
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for 12 h. After cooling to room temperature, the reaction was
quenched with water (5 mL) and extracted with CH2Cl2 (3 × 5 mL).
The combined organic phase was dried over anhydrous Na2SO4,
filtered, and concentrated. The resulting residue was purified by pre-
HPLC to yield the title compound as brown oil (127 mg, 80% yield).
1H NMR (600 MHz, CD3OD): δ 7.74 (s, 1H), 7.71 (s, 1H), 4.26 (t, J
= 5.7 Hz, 2H), 4.16 (s, 3H), 3.82−3.69 (m, 2H), 3.49−3.41 (m, 2H),
3.22−3.11 (m, 2H), 2.40−2.29 (m, 2H), 2.28−2.17 (m, 2H), 2.14−
2.00 (m, 2H). UPLC >95%, tR = 0.95 min.
5-(3-(Isoindolin-2-yl)propoxy)-4-methoxyisophthalonitrile
(11). Compound 11 was synthesized from intermediate 9 according
to the procedures for the preparation of 10 as brown oil (60% yield).
1H NMR (600 MHz, CD3OD): δ 7.72 (dd, J = 3.8, 1.7 Hz, 2H),
7.47−7.44 (m, 4H), 5.00 (br, 2H), 4.66 (br, 2H), 4.31 (t, J = 5.8 Hz,
2H), 4.14 (s, 3H), 3.72−3.69 (m, 2H), 2.49−2.37 (m, 2H). HPLC
>95%, tR = 1.24 min.
Benzyl 3-(Benzyloxy)-5-bromo-4-methoxybenzoate (13). To
a solution of 3-bromo-5-hydroxy-4-methoxybenzoic acid (1.1 g, 4.4
mmol) in DMF (12 mL) was added benzyl bromide (1.1 mL, 9.2
mmol) and K2CO3 (1.6 g, 11.3 mmol). The mixture was stirred at
room temperature for 12 h, before being quenched with water. The
mixture was extracted with ether (3 × 30 mL). The combined organic
phase was dried over anhydrous Na2SO4, filtered, and concentrated.
The resulting residue was purified by flash chromatography to yield
the title compound as the white solid (1.7 g, 91% yield).
Benzyl 3-(Benzyloxy)-5-cyano-4-methoxybenzoate (14).
Compound 14 was synthesized from intermediate 13 according to
the procedures for the preparation of 7 as the brown solid (54%
yield). 1H NMR (600 MHz, CDCl3): δ 7.92 (d, J = 1.8 Hz, 1H), 7.60
(d, J = 1.8 Hz, 1H), 7.57−7.54 (m, 2H), 7.50−7.46 (m, 2H), 7.46−
7.34 (m, 6H), 5.39 (s, 2H), 5.15 (s, 2H), 3.94 (s, 3H). UPLC >95%,
tR = 1.74 min.
3-(Benzyloxy)-5-cyano-4-methoxybenzamide (16). To a
solution of 14 (460 mg, 1.2 mmol) in MeOH (5 mL) was added
aqueous NaOH (1.5 mL, 1 N, 1.5 mmol) solution. The solution was
stirred at room temperature for 2 h, before being acidified with
aqueous HCl (2 mL, 1 N, 2 mmol). The resulting suspension was
filtered. The collected solid was dried and used for the next step
without further purification. The crude acid (370 mg, 1.3 mmol) was
dissolved in CH2Cl2 (5 mL). To the resulting solution was added
(COCl)2 (0.22 mL, 2.6 mmol) and DMF (several drops). The
solution was stirred at room temperature for 1 h, before being
concentrated. The resulting residue was dissolved in CH2Cl2 (5 mL).
To the solution was added aqueous ammonia solution (1 mL, 28%,
14.8 mmol) at 0 °C. The mixture was stirred for 1 h at 0 °C before
being poured into a separatory funnel. The organic phase was
collected. The aqueous phase was extracted with CH2Cl2 (2 × 5 mL).
The organic phase was combined, dried over Na2SO4, filtered, and
concentrated. The resulting residue was purified by flash chromatog-
raphy to yield the title compound as the brown solid (140 mg, 41% in
2 steps). 1H NMR (600 MHz, CDCl3): δ 7.74 (d, J = 1.9 Hz, 1H),
7.67 (d, J = 1.9 Hz, 1H), 7.45−7.41 (m, 2H), 7.35−7.25 (m, 3H),
5.30 (s, 2H), 4.69 (s, 2H), 3.96 (s, 3H). UPLC >95%, tR = 1.29 min.
3-(3-Chloropropoxy)-5-cyano-4-methoxybenzamide (18).
Compound 18 was synthesized from intermediate 16 according to
the procedures for the preparation of 9 as the off-white solid (55%
yield in 2 steps). 1H NMR (600 MHz, CD3OD): δ 7.74 (s, 1H), 7.69
(s, 1H), 4.41 (t, J = 5.6 Hz, 2H), 4.26 (s, 2H), 3.94 (s, 3H), 3.83 (t, J
= 6.2 Hz, 2H), 2.26−2.17 (m, 2H). UPLC >95%, tR = 1.20 min.
3-Cyano-5-(3-(isoindolin-2-yl)propoxy)-4-methoxybenza-
mide (19). Compound 19 was synthesized from intermediate 18
according to the procedures for the preparation of 11 as brown oil
(61% yield). 1H NMR (600 MHz, CD3OD): δ 7.86 (d, J = 2.0 Hz,
1H), 7.79 (d, J = 1.9 Hz, 1H), 7.56−7.35 (m, 4H), 5.06−4.96 (m,
2H), 4.72−4.65 (m, 2H), 4.46 (t, J = 5.6 Hz, 2H), 4.00 (s, 3H),
3.89−3.79 (m, 2H), 2.43−2.27 (m, 2H). UPLC >95%, tR = 0.90 min.
Crystallization and X-ray Cocrystal Structure Determina-
tion. SPIN1Pro49−Ser262 was crystallized with compound 3 at 4 °C
using the sitting drop vapor diffusion method. SPIN1 was incubated
with 1.5 mM of compound 3 using 39 mg/mL protein, and crystals
appeared in drops consisting of 75 nL protein compound mixture and
75 nL precipitant consisting of 60% 2-Methyl-2,4-pentanediol
(MPD), and 0.1 M SPG (succinate, phosphate, and glycine) buffer
pH 6.0. A 1.6 Å resolution dataset was collected on beamline I04 at
Diamond Light Source UK. The dataset was processed, scaled, and
merged at the Diamond Light Source using Xia2.48−52
The structure was solved by molecular replacement using PHASER
and SPIN1 PDB ID 6I8L as a search model. The structure was refined
in PHENIX53 with electron density map inspections and model
improvement in COOT54 and terminated when there were no
significant changes in the Rwork and Rfree values, and inspection of the
electron density map suggested that no further corrections or
additions were justified. Statistics for data collection and refinement
are shown in Table S3. Structural analyses were performed with
PyMOL (http://www.pymol.org) and the coordinates deposited in
PDB with the ID 6QPL.
SPIN1 FP Assay. FP experiments were performed as previously
described.23 The compounds were measured as a 12-point serial
dilution with concentrations ranging from 24 nM to 50 μM, resulting
in a final dimethyl sulfoxide (DMSO) concentration of 0.5%. Blank
values were measured in six wells on the first and last row of the assay
plate. Each concentration as well as positive and negative controls
were tested in triplicates. The incubation time was modified to 30
min.
SPIN1 AlphaLISA Assay. AlphaLISA experiments were per-
formed as previously described.23 The compounds were measured as
a 14-point serial dilution with concentrations ranging from 6.1 nM to
50 μM, resulting in a final DMSO concentration of 0.5%. Blank values
were measured in seven wells on the first and last row of the assay
plate. Each concentration as well as positive and negative controls
were done in triplicates. The incubation time after addition of the
beads was modified to 90 min.
IC50 values were calculated using the combined inhibition values of
two independent experiments and applying a sigmoidal dose−
response fit (variable slope) using GraphPad Prism (version 7).
G9a and GLP ITC Experiments. ITC measurements were made
at 25 °C on a MicroCal ITC200 Instrument (Malvern Instruments).
Coconcentrated G9a−SAM and GLP−SAM (protein/SAM molar
ratio of 1:5) were diluted at 35 μM in ITC buffer [50 mM Tris (pH
8.0), 150 mM NaCl] supplemented with 1% DMSO. Small molecule
compounds were dissolved in DMSO at 50 mM and diluted to 0.5
mM in ITC buffer with a final DMSO concentration of 1%. Binding
constants were calculated by fitting the data using the ITC data
analysis module in Origin 7.0 (OriginLab Corp.).
SPIN1 ITC Experiments. ITC experiments were performed at 20
°C with a MicroCal VP-ITC microcalorimeter (GE Healthcare) by
injection of 8 μL of compound solution (100−300 μM) during 16 s
into the sample cell containing 10 μM of His−SPIN1(49−262) in
ITC assay buffer. DMSO was adapted in a syringe and sample cell to
0.1−0.3%. A total of 33 injections were performed with a spacing of
240 s and a reference power of 10 μcal s−1.
Automated baseline assignment and peak integration were
performed with NITPIC version 1.0.1.55 Isotherms were plotted by
global analysis of multiple titrations, with the simplex algorithm, with
SEDPHAT version 10.58d.56 Isotherms were subsequently validated
by two-dimensional error surface projections at P levels of 0.68 and
0.95 in SEDFIT.57
Other SPIN Subfamily ITC Experiments. Purified protein was
diluted to 10−30 μM in ITC buffer (100 mM NaCl, 20 mM Tris, pH
8.0) and then dialyzed against a 1000 times excess of ITC buffer at 4
°C overnight using D-Tube Dialyzer tubes (Merck/Sigma-Aldrich)
with a 3.5 kDa molecular weight cut-off. The dialyzed sample was
then centrifuged at 14 000 rpm for 10 min in a standard chilled
benchtop centrifuge at 4 °C. Protein concentration was then verified
via absorption at 280 nm using a NanoDrop ND1000 Spectropho-
tometer. Compounds were diluted to 200 μM in ITC buffer.
Experiments were performed on a NanoITC Standard Volume
instrument (960 μL cell volume, 250 μL syringe volume; TA
Instruments) using direct titration (protein in cell, compound in
syringe) at 20 °C, a stir rate of 350 rpm, and an injection rate of 50
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ms/step (∼1.4 μL/s). An initial injection of 3.7 μL followed after 200
s by 30 injections of 7.96 μL spaced at 300 s. Data were analyzed
using an independent fit model with the NanoAnalyse software (TA
Instruments, version 3.8.0).
Thermal Shift (Tm) Assay. Compounds were dispensed on white
PCR plates using an Echo 550 acoustic liquid dispenser to a final
concentration of 20 or 200 μM with two technical replicates per
concentration per protein. Protein in Tm shift buffer (20 mM HEPES,
500 mM NaCl, pH 7.5, SYPRO orange dye at 1:1000 dilution from
purchased stock) was added at 2 μM final concentration. The lower
concentrations were back-filled with DMSO to the same amount
dispensed as for the highest concentration, and DMSO-only controls
were also included (n = 4 per protein). Experiments were performed
on Agilent Mx3005P qPCR machines (reaction volume 20 μL) or
Roche Lightcycler 480 (reaction volume 5 μL). The temperature
gradient was run from 25 to 95 °C over 25 min. Melting temperatures
Tm were estimated as the inflection point of a Boltzmann equation
fitted to the fluorescence intensity I(T) from the onset (Ionset) to the
peak (Ipeak) of intensity where S is the slope of the curve
= + − + −I T I I I( ) ( )/1 e T T Sonset peak onset
(( )/ )m
Shifts in unfolding (DTm) were then calculated as the difference
between the individual Tm from the mean of the DMSO controls.
MT and Acetyltransferase Selectivity Assays. The effect of
compound 3 on activities of 33 MTs and 5 acetyltransferases was
assessed using activity assays as previously described.58
NanoBRET Assay. U20S cells (2.8 × 105) were plated in each well
of a 6-well plate. After 6 h cells were cotransfected with C-terminal
HaloTag−histone 3.3 (NM_002107) and an N-terminal Nano-
Luciferase fusion of full length SPIN1 at a 1:500 (NanoLuc to
HaloTag) ratio, respectively, with a FuGENE HD transfection
reagent. 16 h post-transfection, cells were collected, washed with
phosphate-buffered saline, and exchanged into media containing
phenol red-free Dulbecco’s modified Eagle’s medium (DMEM) and
4% fetal bovine serum (FBS) in the absence (control sample) or the
presence (experimental sample) of the 100 nM NanoBRET 618
fluorescent ligand (Promega). Cells were then replated in a 384-well
assay white plate (Greiner #3570) at 2.7 × 103 cells per well.
Compound 3 and compound 4 were then added directly to media at
final concentrations 0−30 μM or an equivalent amount of DMSO as a
vehicle control, and the plates were incubated for 24 h at 37 °C in the
presence of 5% CO2. The NanoBRET Nano-Glo substrate (Promega)
was added to both control and experimental samples at a final
concentration of 10 μM. Readings were performed within 10 min
using ClarioSTAR (BMG Labtech). A corrected BRET ratio was
calculated and is defined as the ratio of the emission at 610 nm/460
nm for experimental samples minus the emission at 610 nm/460 nm
for control samples (without NanoBRET fluorescent ligand). BRET
ratios are expressed as milliBRET units (mBU), where 1 mBU
corresponds to the corrected BRET ratio multiplied by 1000. The
assay was further validated by the domain-specific site directed
mutagenesis (Y170A) ablating peptide and ligand binding.
Cell Viability Assay. 293T (gift from Dr. Benchimol), C2C12
(gift from Dr. McPherson), and HFF1 (ATTC) cells were cultured
following standard protocols in DMEM (Gibco) 10% FBS (Wisent)
and penicillin−streptomycin (Gibco). Cells were seeded in 96-well
plates (seeding density: 2000 for HFF-1, 1000 for 293T and 500 for
C2C12), recovered for 8 h, and treated with several different
concentrations of compound 3 for 6 days. Following cell treatment,
cell viability was measured by adding resazurin (Sigma) to the media
at 0.01 mg/mL, incubating plates for 2−4 h in a 37 °C CO2 incubator,
and measuring fluorescence at 590 nm on a CLARIOstar microplate
reader (BMG Labtech).
Construct Design, Cloning, Expression, and Purification of
Human Spindlin Proteins. A plasmid-encoding full-length human
SPIN1 was obtained from Source Bioscience (IOH9972-pDEST26)
and used as a template to clone SPIN1M26−Ser262 and SPIN1P49−S262
into the pNIC-CTHF vector with a TEV (tobacco etch virus)
cleavable C-terminal His6 tag. SPIN1G21−S262 was cloned into the
pNIC-Bio2 vector with a TEV cleavable N-terminal His10 tag and a C-
terminal biotinylation sequence. SPI2BP45−S258, SPIN3M27−S258, and
SPIN4T36−P249 were cloned into the pNIC vector with a TEV
cleavable N-terminal His6 tag using templates obtained from the
Mammalian Gene Collection and Source Bioscience (SPIN2B: cDNA
clone IMAGE id: 6729986, SPIN3 IMAGENE: IRCBp5005F0211Q
and SPIN4 IMAGE id 40032302). The recombinant proteins were
expressed in a phage-resistant derivative of Escherichia coli strain
BL21(DE3) carrying the pRARE2 plasmid for rare codon expression.
Cells were grown at 37 °C in Terrific broth supplemented with 50
μg/mL kanamycin and 34 μg/mL chloramphenicol, until the culture
reached an OD600 of 2.0. The temperature was decreased to 18 °C
and protein expression induced with 0.1 mM IPTG (isopropyl β-D-
thiogalactopyranoside) overnight. Cells were collected by centrifuga-
tion and frozen at −80 °C. For purification, cells were resuspended in
50 mM HEPES pH 7.5, 500 mM NaCl, 10 mM imidazole, 5%
glycerol, 0.5 mM TCEP, and a protease inhibitor cocktail (Sigma),
and lysed by sonication. The cell lysate was clarified by centrifugation,
and the proteins were purified by nickel-affinity chromatography (GE
Healthcare) using a stepwise gradient of imidazole. This was followed
by size exclusion chromatography (Superdex 75 or Superdex 200, GE
Healthcare) as previously described.23 For the ITC assay, aliquots of
purified His−SPIN1(49−262) protein were stored at −80 °C in the
ITC assay buffer containing 20 mM Tris-HCl (pH 8.0), 200 mM
NaCl. For crystallization studies, the histidine tag was removed by
incubation with TEV protease at 4 °C overnight, and the TEV
protease and the uncleaved proteins were then removed by nickel-
affinity chromatography. Proteins were concentrated using an Amicon
centrifugal filtration unit, and the mass was verified by ESI time of
flight mass spectrometry (ESI-TOF-TOF: Agilent LC/MSD).
Construct Design, Cloning, Expression, and Purification of
G9a and GLP Proteins. Human G9a and GLP catalytic domains
were cloned, expressed, and purified as previously described.59
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Robers, M. B.; Zimmerman, K.; Otto, P.; Daniels, D. L.; Kirkland, T.
A.; Wood, K. V. NanoBRETa novel BRET platform for the analysis
of protein−protein interactions. ACS Chem. Biol. 2015, 10, 1797−
1804.
(47) Green, K. Improved metalation of 2,4,6-tribromoanisole -
sythesis of 2-methoxyresorcinol. J. Org. Chem. 1991, 56, 4325−4326.
(48) Evans, P. Scaling and assessment of data quality. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 72−82.
(49) Axford, D.; Foadi, J.; Hu, N.-J.; Choudhury, H. G.; Iwata, S.;
Beis, K.; Evans, G.; Alguel, Y. Structure determination of an integral
membrane protein at room temperature from crystals in situ. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 2015, 71, 1228−1237.
(50) Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.;
Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.
W.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.;
Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S.
Overview of the CCP4 suite and current developments. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67, 235−242.
(51) Winter, G. xia2: an expert system for macromolecular
crystallography data reduction. J. Appl. Crystallogr. 2010, 43, 186−
190.
(52) Winter, G.; Waterman, D. G.; Parkhurst, J. M.; Brewster, A. S.;
Gildea, R. J.; Gerstel, M.; Fuentes-Montero, L.; Vollmar, M.; Michels-
Clark, T.; Young, I. D.; Sauter, N. K.; Evans, G. DIALS:
implementation and evaluation of a new integration package. Acta
Crystallogr., Sect. D: Struct. Biol. 2018, 74, 85−97.
(53) Adams, P. D.; Afonine, P. V.; Bunkoćzi, G.; Chen, V. B.; Davis,
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